Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)

NCT03905707 is registered in ClinicalTrials.gov with Zealand Pharma as lead sponsor.

NCT NCT03905707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03905707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
Lead sponsor
Zealand Pharma
Phase
Phase 3
Overall status
Completed
Start date
May 7, 2019
Completion date
April 30, 2026
Enrollment
150 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

short bowel syndrome